Medicare drug coverage

Takhzyro: 2027 Medicare Part D coverage

311 of 5,495 Part D plans (6%) list Takhzyro on their 2027 formulary, down 1 point from 2026. 64% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Takhzyro is number 179 by total Medicare Part D spending in 2024 ($223 million). Plans that list it most often put it on tier 5. Counts use 4 RxNorm products for this name.

Takhzyro Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it374 (7%)311 (6%)-1 point
Prior authorization (of plans that list it)259 (69%)199 (64%)-5 points
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)156 (42%)148 (48%)+6 points
Any of the three (of plans that list it)259 (69%)199 (64%)-5 points
Not listed or restricted (of all plans)5,403 (98%)5,383 (98%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Takhzyro formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 12 (1%)4 (1%)
Tier 21 (0%)0 (0%)
Tier 47 (2%)7 (2%)
Tier 5344 (92%)300 (96%)
Tier 620 (5%)0 (0%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 0 of them (0%) added prior authorization, step therapy, or a quantity limit for Takhzyro, and 3 stopped listing it.

Takhzyro: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 20273 (0%)
Listed it in 2027, not in 20262 (0%)
Moved it to a higher tier0 (0%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit0 (0%)
Added at least one of the three0 (0%)
Removed at least one of the three0 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Takhzyro off the formulary or list it with prior authorization, step therapy, or a quantity limit. Pennsylvania ranks first at 100%, with 13% of its plans using prior authorization or step therapy; Maryland ranks last at 80%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for Takhzyro, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Pennsylvania324100%13%no change
2New York215100%13%no change
3Florida549100%7%no change
4Ohio173100%5%no change
5New Mexico68100%4%no change
6Arizona148100%4%no change
7Texas412100%3%no change
8Alaska9100%0%no change
9Alabama115100%0%no change
10Arkansas86100%0%no change
11Connecticut54100%0%no change
12Delaware43100%0%no change
13Iowa64100%0%no change
14Idaho45100%0%no change
15Illinois133100%0%no change
16Indiana140100%0%no change
17Kansas84100%0%no change
18Kentucky123100%0%no change
19Louisiana126100%0%no change
20Massachusetts92100%0%no change
21Maine52100%0%no change
22Michigan183100%0%no change
23Minnesota63100%0%no change
24Missouri171100%0%no change
25Mississippi105100%0%no change
26Montana27100%0%no change
27North Carolina177100%0%no change
28North Dakota26100%0%no change
29Nebraska51100%0%no change
30New Hampshire25100%0%no change
31New Jersey74100%0%no change
32Oklahoma81100%0%no change
33Rhode Island29100%0%no change
34South Carolina91100%0%no change
35South Dakota30100%0%no change
36Tennessee157100%0%no change
37Utah53100%0%no change
38Vermont14100%0%no change
39Wisconsin97100%0%no change
40West Virginia70100%0%no change
41Wyoming13100%0%no change
42Nevada10097%10%-3 points
43Virginia14596%0%no change
44Oregon9296%1%no change
45Georgia15195%0%no change
46Colorado10690%1%+3 points
47Hawaii5088%0%+1 point
48California39788%2%no change
49Washington11486%0%+1 point
50District of Columbia2186%0%-2 points
51Maryland4980%0%-5 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Takhzyro off or restrict it.

Takhzyro coverage by parent organization, 2027
Parent organization2027 plans ↓List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
Humana Inc.8840%none list it100%no change0
UnitedHealth Group, Inc.8500%none list it100%no change0
Devoted Health, Inc.7280%none list it100%no change0
CVS Health Corporation6330%none list it100%no change0
Elevance Health, Inc.29413%100%100%no change0
Centene Corporation2680%none list it100%no change0
Health Care Service Corporation2310%none list it100%no change0
Kaiser Foundation Health Plan, Inc.112100%0%0%no change0
Highmark Health980%none list it100%no change0
SCAN Group850%none list it100%no change0
Alignment Healthcare USA, LLC770%none list it100%no change0
Guidewell Mutual Holding Corporation550%none list it100%no change0
Blue Cross Blue Shield of Michigan Mutual Ins. Co.430%none list it100%no change0
Molina Healthcare, Inc.430%none list it100%no change0
Corewell Health400%none list it100%no change0
Zing Health Consolidator, Inc360%none list it100%no change0
CAPITAL BLUE CROSS350%none list it100%no change0
Medica Holding Company310%none list it100%no change0
UPMC Health System30100%100%100%no change0
Universal Health Services, Inc.29100%100%100%no change0
MHH Healthcare, L.P.2677%100%100%no change0
Independence Health Group, Inc.250%none list it100%no change0
Point32Health, Inc.230%none list it100%no change0
BlueCross BlueShield of Tennessee220%none list it100%no change0
California Physicians' Service220%none list it100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Takhzyro?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing